Imidin N

Xylometazoline Hydrochloride, the active ingredient in Imidin N, is an alpha‑adrenergic agonist presented as a nasal spray for topical nasal use. It relieves nasal congestion associated with the common cold, allergic rhinitis and sinusitis in adults and children.

GNH USA supplies Imidin N as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Xylometazoline Hydrochloride is used to treat nasal congestion by acting on the nasal mucosa.

- Common cold: reduces nasal blockage and improves airflow. - Allergic rhinitis: alleviates congestion caused by allergic inflammation. - Sinusitis: diminishes swelling of nasal passages to ease sinus drainage.

Adverse reactions may occur with nasal administration of Xylometazoline Hydrochloride.

Common Side Effects: - Nasal burning or stinging - Sneezing - Dryness of nasal mucosa - Headache

Serious or Rare Side Effects: - Rebound congestion with prolonged use - Hypertension (rare)

When using Imidin N, consider the following safety measures.

- Duration of use: limit to 3‑5 days to avoid rebound congestion. - Underlying conditions: avoid if the patient has severe hypertension or coronary artery disease. - Age restrictions: not recommended for children under 2 years without medical advice. - Concomitant nasal medications: do not combine with other vasoconstrictive nasal sprays. - Pregnancy and lactation: safety not established; use only if clearly needed. - Store at ambient temperature: keep below 25 °C, protect from moisture and direct sunlight, retain in the original container.

Xylometazoline Hydrochloride may interact with other medicines.

Major Interactions (Avoid): - Monoamine oxidase inhibitors (MAOIs): may potentiate systemic vasoconstrictive effects. - Other nasal decongestants (e.g., phenylephrine, oxymetazoline): risk of excessive vasoconstriction.

Moderate Interactions (Monitor Closely): - Antihypertensive agents: monitor blood pressure as nasal vasoconstriction may affect systemic pressure. - Beta‑blockers: possible additive cardiovascular effects. - Tricyclic antidepressants: may increase risk of hypertension.